Financial Survey: PainReform (NASDAQ:PRFX) & Alaunos Therapeutics (NASDAQ:TCRT)

Alaunos Therapeutics (NASDAQ:TCRT) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Volatility & Risk

Alaunos Therapeutics has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500. Comparatively, PainReform has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Insider & Institutional Ownership

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Alaunos Therapeutics and PainReform’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-167.97%	-120.74%
PainReform	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Alaunos Therapeutics and PainReform, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1	0	0	0	1.00
PainReform	1	0	0	0	1.00

Valuation and Earnings

This table compares Alaunos Therapeutics and PainReform”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.68 million	($2.31)	-1.28
PainReform	$20,000.00	42.20	-$5.02 million	($736.66)	0.00

Alaunos Therapeutics has higher earnings, but lower revenue than PainReform. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Summary

PainReform beats Alaunos Therapeutics on 7 of the 9 factors compared between the two stocks.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.